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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
onabotulinumtoxin-A decreases the frequency of headaches in adults with chronic migraines.  
 
Study design: A review of two randomized controlled trials and one observational cohort that 
were published in peer-reviewed journals between 2010-2016.  
 
Data sources: The study reviews were searched through PubMed and were selected based on 
types of studies, years they were published, relevance to the clinical question, and outcomes that 
were patient oriented.  
 
Outcomes measured: Patient recorded headache diaries and telephone diaries were used to 
record the frequency of headaches. Any headache lasting >4 hours were recorded as headache 
days in the Diener et al study, while no headache at all was recorded as headache free-day in the 
Mathew et al. study.6,7 
 
Results: In the study conducted by Vikelis et al., results showed a decrease in the frequency of 
headaches with a p-value <.001.8 In the Mathew et al. study, the results show that decrease of 
50% or more was greater in the onabotulinumtoxin-A group compared to placebo; p-value 
<.027.6 The second study, conducted by Diener et al., showed that patients treated with 
onabotulinumtoxin-A had a significant change from headache day baseline compared to placebo 
(p<.001)7  
 
Conclusion: Based off of the results from the studies, it is clear that onabotulinumtoxin-A 
decreases the frequency of headaches. All three studies show significant data that support the use 
of onabotulinumtoxin-A in decreasing frequency of chronic migraines. Studies used mean 
change from baseline and decrease of headache free days out of the month to measure their 
outcome.  
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Introduction  
Migraines are the leading cause of neurologic disability and affect 10% of people 
worldwide and about 4 million people in the US.1 A migraine is a benign and recurring type of 
headache associated with neurologic dysfunction. They can be accompanied with or without an 
aura, although without aura is more common.2 Migraines are three times more common in 
women, and are the second most common cause of a headache.2,3 Chronic migraine is defined as 
experiencing migraines more than 15 days out of the month.  
Headaches are a very common complaint in the emergency department and account for 
about 1.2 million visits each year.4 It is estimated that $78 billion is spent on migraines in the 
United States each year. This number includes all different types of headaches, acute and 
chronic. Specifically, $9,364 is spent annually on those dealing with chronic migraines.5   
The specific mechanism of action of migraines is not proven, but it is based on the 
hypothesis and knowledge of what is known about the brainstem pathways. It is believed that 
serotonin and dopamine play a role in the pathophysiology of migraines, but their exact 
mechanism is unclear.1 It is known that migraine attacks have a familial component. Mutations 
involving CACNA1A gene are known to cause familial hemiplegic migraines (FHM).1  
Key components of migraine include throbbing or pulsatile pain, nausea, vomiting, 
photosensitivity, and pain that is made worse with movement.1 The usual methods of treatment 
for migraines include: avoidance of triggering factors, acetaminophen, ibuprofen, naproxen, 
triptans, ergotamines, prochlorperazine, metoclopramide, transcranial magnetic stimulation, and 
narcotics.1 Propranolol, amitriptyline, and topiramate can all be used as preventative treatment in 
patients with chronic migraines.2. Botox injections can be used as an alternative treatment to 
decrease the severity and frequency of migraines in treatment resistant patients.  
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 Botulinum toxin type A inhibits the release of acetylcholine at the neuromuscular 
junction. It is focally administered and is used therapeutically in disorders characterized by 
muscle hyperactivity. Onabotulinumtoxin-A can help to treat chronic migraines since it also 
inhibits the release of nociceptive mediators such as glutamate substance P, and calcitonin gene-
related peptide.6  
Objective  
The objective of this selective EBM review is to determine whether or not “Does 
onabotulinumtoxin-A decrease the frequency of headaches in adults with chronic migraines?” 
Methods 
Two randomized controlled trials and one observational cohort were used in order to help 
answer our clinical question. All three articles were found through the database PubMed. Key 
words such as botulinum toxin A, chronic migraine, prophylaxis, and chronic daily headache 
were all used to help find the appropriate articles. Since the clinical question focused on adults, 
articles were selected based on participants that were between the ages of 18-65. 
 Articles were selected based on types of studies, years they were published, relevance to 
the clinical question, and outcomes that were patient oriented. All articles were published in 
English in peer-reviewed journals. Inclusion criteria included studies that were RCT and 
published after 2009. Exclusion criteria were any studies that included patients less than 18 years 
old. A summary of statistics reported were change from baseline, NNT, EER, CER, and p-value, 
and a decrease of 50% or more from baseline.  
Patients greater than 18 years old who experienced headaches more than 15 days of the 
month were used as the population studied in all three studies. The intervention in all three 
studies was onabotulinumtoxin-A 100 IU, and 155 IU. The two randomized controlled trials had 
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placebo groups which used sodium chloride for comparison. The observational cohort used 
patient’s pre-treatment status for comparison.  
 
Table 1- Demographics & characteristics of included studies  
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Outcomes  
Patient recorded headache diaries, telephone diaries, and severity by numerical scale 
were all used to measure the frequency of headaches. A headache impact test score and 
migraine-specific quality of life questionnaire were also used to measure change from patient’s 
baseline. A decrease from baseline of 50% or more was considered a significant change when 
measuring frequency of headaches. Researchers in the Diener et al. study counted a headache-
free day if the patient reported a headache that lasted <4 hours in a 24-hour day.7 In the Mathew 
et al. study, a headache-free day was recorded as no headache at all during a 24-hour period.6 
 
Results  
All studies included adults aged 18 to 65 years old with chronic migraines 15 days or 
more out of a 30-day period. Two randomized controlled trials and one observational cohort 
compared onabotulinumtoxin-A against either placebo or patient’s baseline to determine if 
onabotulinumtoxin-A was able to decrease the frequency of migraines. All inclusion and 
exclusion criteria for each study can be found in table 1.  
The study conducted by Mathew et al. used mean change from baseline to measure 
frequency of headaches. This was determined using patient recorded telephone diaries.  Patients 
in the study were also asked to record the use of other acute pain medications using electronic 
data system. This gave researchers the ability to compare the use of onabotulinumtoxin-A against 
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Patients were screened during a 30-day baseline period using electronic telephone diaries, 
which captured specific characteristics of their headaches as well as use of medication.6 Of the 
571 patients assessed over the baseline period, 355 were enrolled and randomized. 279 patients 
were classified as placebo nonresponders and 76 patients are placebo responders. Patients were 
randomized within each group to receive either onabotulinumtoxin-A or placebo.6 
A difference of three headache-free days between the onabotulinumtoxin-A and placebo 
group, per 30-day period, was considered to be statistically significant. A headache free day was 
defined as no headache after a complete day (00.00-23.59).6 A significantly higher percentage of 
participants in the placebo nonresponder group was noted on day 180 to have a decrease of 50% 
or more in the frequency of headaches per 30-day period (32.7% vs 15%, p=.027).6 This means 
that 32% of participants receiving onabotulinumtoxin-A had a decrease of 50% or more of 
headache free days compared to placebo. Also, the mean change from baseline in the frequency 
of headaches per 30-day period was -6.1 for the onabotulinumtoxin-A group vs -3.1 for placebo 
group (p=.013).6 NNT was calculated and are shown in table 2.  
 





The second study, conducted by Diener et al., was the second part of the PREENPT 2 
trial that compared onabotulinumtoxin-A versus placebo to measure frequency of headaches in 
adults over a 24-week period.7 Patients who qualified for the study were randomized in a 1:1 
double-blind fashion to experimental group using onabotulinumtoxin- or placebo.7 Throughout 
Group  ARR NNT 
Non-responder 0.11 9 
Responder  0.28 4 
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the entire double-blind phase, the participants, investigators, and experimenters were all masked 
to the treatment-group. 
Injections were administered at 31 fixed-sites intramuscularly.7 The primary efficacy 
endpoint of this study was mean change from baseline in frequency of headache days for the 28-
day period. A headache day was defined as a calendar day (24 hours) with four or more hours 
consisting of a headache. Throughout the study, patient’s headaches were recorded using an 
interactive voice response system and telephone diaries. 
In the end of the 24 week period study, results proved that Onabotulinumtoxin-A was 
significantly superior compared to placebo in reducing frequency of headaches compared to 
baseline (-9.0 in Onabotulinumtoxin-A versus -6.7 in placebo group, p < 0.001).7 Results showed 
a 95% CI (-3.35, -1.31) which means that the researchers were 95% confident that the mean of 
headache-free days for patients in the intervention group was between the values of -3.35 and -
1.31.7  
Vikelis et al. was an observational cohort study that used onabotulinumtoxin-A versus 
patients baseline to measure the efficacy of onabotulinumtoxin-A decreasing frequency of 
headaches.8 Headaches were recorded using diaries at each scheduled visit. For safety control, 
patients were encouraged to report any side effects of the treatment either spontaneously or in 
non-direct questioning. Patients who could not tolerate the treatment withdrew from the program. 
Overall the intervention was considered generally safe and side effects were non-severe.8 
Of the 81 patients who did complete the study, results showed a significant decrease in 
mean days out of the month between months 0-3 (21.3 +/- 5.4 versus 7.7 +/- 4.8; p-value 
<0.001).8 This means that participants experienced on average only 7.7 days of headaches 
compared to their baseline which was about 21.3 days, on a 30-day period.  
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Discussion 
All three studies conducted by Diener et al., Vikelis et al., and Mathew et al. showed 
onabotulinumtoxin-A was able to decrease the frequency of headaches in adults with chronic 
migraines.7,8 A decrease of 50% or more was observed in Mathew et. al study, while the other 
two studies were able to show decrease of headache free days with p-values and CI.  
Between all three studies, there is some variation in the amount of onabotulinumtoxin-A 
used as intervention. Therefore, we can only use a range of onabotulinumtoxin-A to say what 
amount is needed to reduce frequency of headache days. There was also difference in location of 
where the onabotulinumtoxin-A was injected between the three studies. Two of the studies 
injected in a total of 7 intramuscular sites, while the third study did not list their injection sites. 
Also, two of the studies used a follow-the-pain strategy, while the third did not. This means, 
additional dosing was allowed per protocol depending on the patient’s predominant pain and 
severity of migraine.7 All three studies used different times periods for the duration of their 
treatment. Time periods ranged from 12 weeks to 36 weeks.6,7,8 The study conducted by Diener 
et. al. also took into consideration other treatment options being used throughout the study, like 
acute pain medication, while the others did not. 
One limitation to this research, was the types of studies selected for my paper. The 
observational cohort study provided limited data and statistical analysis. NNT could not be 
calculated for this study since there was no control group.8 RCTs are the gold standard for 
clinical research and have a high impact on clinical guidelines. This is because RCTs have both 
experimental and control groups that are randomized which reduces selection bias. Another 
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All three studies showed that onabotulinumtoxin-A is able to decrease frequency of 
headaches in adults with chronic migraines. Both of the RCTs provided significant data which 
supported the use of onabotulinumtoxin-A for chronic migraines. The observation cohort was 
able to prove efficacy by comparing end results to patient’s baseline. However, there is some 
discrepancy between the studies as far as time periods, injection site, and amount of treatment 
used.  
Further research needs to be conducted to answer the clinical question “Does 
onabotulinumtoxin-A decrease the frequency of headaches in adults with chronic migraines?”. 
This selective EBM paper focused specifically on the frequency of migraines affected by the 
onabotulinumtoxin-A treatment. The severity of migraines is another factor that needs to be 
considered from the use of onabotulinumtoxin-A for migraines. Only two of the three articles 
focused on severity of participant’s migraines. One study also looked at other acute pain 
medications during the duration of the treatment. This gave researchers the ability to compare 
onabotulinumtoxin-A to other migraine treatment options. Future research should focus on these 
components, as well as longer time periods of treatment, consistency in amount used, and 
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